<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02904226</url>
  </required_header>
  <id_info>
    <org_study_id>JTX-2011-101</org_study_id>
    <nct_id>NCT02904226</nct_id>
  </id_info>
  <brief_title>JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors</brief_title>
  <acronym>ICONIC</acronym>
  <official_title>Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone and in Combination With Nivolumab, Ipilimumab, or Pembrolizumab in Adult Subjects With Advanced and/or Refractory Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jounce Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jounce Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      JTX-2011-101 is a Phase 1/2, open label, dose escalation and expansion clinical study of&#xD;
      JTX-2011 alone and in combination with nivolumab, ipilimumab, or pembrolizumab in adult&#xD;
      subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated&#xD;
      dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      JTX-2011 is an agonist monoclonal antibody that specifically binds to the Inducible&#xD;
      CO-Stimulator of T cells (ICOS) to generate an anti-tumor immune response. This is a Phase&#xD;
      1/2, open label, multicenter, dose escalation and expansion, first-in-human (FIH) clinical&#xD;
      study to evaluate the safety and tolerability, PK, PD, and preliminary efficacy of the ICOS&#xD;
      agonist monoclonal antibody JTX-2011 alone and in combination with nivolumab, ipilimumab, or&#xD;
      pembrolizumab in adult subjects with advanced and/or refractory solid tumors. The study will&#xD;
      include a dose escalation phase for single agent and the combination therapies, followed by&#xD;
      an expansion phase in specified tumor types for single agent and the combination therapies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAE)</measure>
    <time_frame>46.3 months</time_frame>
    <description>Number of participants with an adverse event occurring from the time of informed consent until resolution or new therapy initiated or for 28 days post final dose if no new therapy is initiated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Grade 5 (Fatal) Treatment Emergent Adverse Events (TEAE)</measure>
    <time_frame>46.3 months</time_frame>
    <description>Number of participants with Grade 5 (fatal) treatment emergent adverse events (TEAE) assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Grade 4 (Life Threatening) Treatment Emergent Adverse Events (TEAE)</measure>
    <time_frame>46.3 months</time_frame>
    <description>Number of participants with Grade 4 (life threatening) treatment emergent adverse events (TEAE) assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Grade 3 (Sever) Treatment Emergent Adverse Events (TEAE)</measure>
    <time_frame>46.3 months</time_frame>
    <description>Number of participants with Grade 3 (severe) treatment emergent adverse events (TEAE) assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Grade 2 (Moderate) Treatment Emergent Adverse Events (TEAE)</measure>
    <time_frame>46.3 months</time_frame>
    <description>Number of participants with Grade 2 (moderate) treatment emergent adverse events (TEAE) assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Grade 1 (Mild) Treatment Emergent Adverse Events (TEAE)</measure>
    <time_frame>46.3 months</time_frame>
    <description>Number of participants with Grade 1 (mild) treatment emergent adverse events (TEAE) assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Dose Limiting Toxicities</measure>
    <time_frame>33 months</time_frame>
    <description>Number of participants with at least one dose limiting toxicity (DLT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>46.5 months</time_frame>
    <description>Overall response rate (ORR) is defined as the proportion of subjects with a Best Overall Response characterized as either a Complete Response (CR) or Partial Response (PR) as defined by RECISTv1.1 guidelines based on investigator's review</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>46.5 months</time_frame>
    <description>Disease Control Rate: Percent Subjects with confirmed Complete Response + confirmed Partial Response + BoR of SD (or unconfirmed complete response or partial response lasting at least 53 days from the date of first dose)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>46.5 months</time_frame>
    <description>Progression free survival, as determined by the Investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 Month Landmark Progression Free Survival</measure>
    <time_frame>46.5 months</time_frame>
    <description>Percentage of patients that are progression free at 6 months, estimated by the Kaplan Meier method as the probability of being event-free at 6 months out of the entire 45.5-month primary study period. This method generates survival probability estimates across the Time Frame of the study using all data throughout the course of the trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12 Month Landmark Progression Free Survival</measure>
    <time_frame>46.5 months</time_frame>
    <description>Percentage of patients that are progression free at 12 month, estimated by the Kaplan Meier method as the probability of being event-free at 12 months out of the entire 45.5-month primary study period. This method generates survival probability estimates across the Time Frame of the study using all data throughout the course of the trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Landmark Overall Survival at 6 Months</measure>
    <time_frame>46.5 months</time_frame>
    <description>Percentage of patients that are alive at 6 month, estimated by the Kaplan Meier method as the probability of being event-free at 6 months out of the entire 45.5-month primary study period. This method generates survival probability estimates across the Time Frame of the study using all data throughout the course of the trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Landmark Overall Survival at 12 Months</measure>
    <time_frame>46.5 months</time_frame>
    <description>Percentage of patients that are alive at 12 month, estimated by the Kaplan Meier method as the probability of being event-free at 12 months out of the entire 45.5-month primary study period. This method generates survival probability estimates across the Time Frame of the study using all data throughout the course of the trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>46.5 months</time_frame>
    <description>The time from first dose date to the date of death for any cause</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Part A (JTX-2011)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (JTX-2011 + nivolumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C (JTX-2011)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2 expansion of JTX-2011 by IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D (JTX-2011 + nivolumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part E (JTX-2011 + ipilimumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part F (JTX-2011 + ipilimumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part G (JTX-2011 + pembrolizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part H (JTX-2011 + pembrolizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JTX-2011</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part A (JTX-2011)</arm_group_label>
    <arm_group_label>Part B (JTX-2011 + nivolumab)</arm_group_label>
    <arm_group_label>Part C (JTX-2011)</arm_group_label>
    <arm_group_label>Part D (JTX-2011 + nivolumab)</arm_group_label>
    <arm_group_label>Part E (JTX-2011 + ipilimumab)</arm_group_label>
    <arm_group_label>Part F (JTX-2011 + ipilimumab)</arm_group_label>
    <arm_group_label>Part G (JTX-2011 + pembrolizumab)</arm_group_label>
    <arm_group_label>Part H (JTX-2011 + pembrolizumab)</arm_group_label>
    <other_name>ICOS agonist monoclonal antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part B (JTX-2011 + nivolumab)</arm_group_label>
    <arm_group_label>Part D (JTX-2011 + nivolumab)</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part E (JTX-2011 + ipilimumab)</arm_group_label>
    <arm_group_label>Part F (JTX-2011 + ipilimumab)</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part G (JTX-2011 + pembrolizumab)</arm_group_label>
    <arm_group_label>Part H (JTX-2011 + pembrolizumab)</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be willing and able to participate and comply with all trial requirements and&#xD;
             able to provide signed and dated informed consent prior to initiation of any trial&#xD;
             procedures&#xD;
&#xD;
          2. Evaluable or measurable disease, according to Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST) v1.1 criteria, and meet the requirements for the intended study cohort&#xD;
&#xD;
          3. Male or Female ≥ 18 years of age&#xD;
&#xD;
          4. Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.&#xD;
             Subjects with ECOG 2 may be considered for enrollment in Parts C, D, F, and H if&#xD;
             approved by Medical Monitor&#xD;
&#xD;
          5. Have a predicted life expectancy of ≥ 3 months&#xD;
&#xD;
          6. Have laboratory values (obtained ≤ 28 days prior to first infusion day) in accordance&#xD;
             with the study protocol&#xD;
&#xD;
          7. If medical history of the following, case should be reviewed by the Medical Monitor:&#xD;
             prior biliary tract disorders (as based on Hepatobiliary SOC high level terms of:&#xD;
             obstructive bile duct disorders, hepatic vascular disorders, structural and other bile&#xD;
             duct disorders) or portal hypertension and/or hepatic vascular disorders&#xD;
&#xD;
          8. Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test at&#xD;
             screening and a negative urine pregnancy test prior to administration of each dose of&#xD;
             JTX-2011&#xD;
&#xD;
          9. WOCBP and males with partners of child-bearing potential must agree to use adequate&#xD;
             birth control throughout their participation and for 5 months following the last study&#xD;
             treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Receiving concurrent anti-cancer treatment (excluding radiation therapy), either&#xD;
             approved or investigational&#xD;
&#xD;
          2. Have refused standard therapy&#xD;
&#xD;
          3. Have received anti-cancer therapies listed below within the specified timeframe, or&#xD;
             who have ongoing toxicity from prior therapy &gt; Grade 1 according to the Common&#xD;
             Terminology for Adverse Events (CTCAE). Exceptions to this are: &gt; Grade 1 toxicities&#xD;
             which in the opinion of the Investigator should not exclude the subject (e.g.&#xD;
             alopecia, Grade 2 neuropathy, hypo- or hyperthyroidism or other endocrinopathies that&#xD;
             are well-controlled with hormone replacement) and are approved by the Medical Monitor.&#xD;
&#xD;
               1. Have received biologic therapy, including immunotherapy, &lt; 28 days prior to C1D1;&#xD;
&#xD;
               2. Have received CAR-T therapy;&#xD;
&#xD;
               3. Have received chemotherapy &lt; 21 days prior to C1D1, or &lt; 42 days for mitomycin or&#xD;
                  nitrosoureas;&#xD;
&#xD;
               4. Have received targeted small molecule therapy &lt; 14 days prior to C1D1;&#xD;
&#xD;
               5. Have undergone organ transplantation including allogeneic or autologous stem-cell&#xD;
                  transplantation, at any time;&#xD;
&#xD;
          4. Have undergone a major surgery (excluding minor procedures, e.g. placement of vascular&#xD;
             access, biopsy, etc.) &lt; 6 months prior to the first day of study treatment, C1D1&#xD;
&#xD;
          5. Have a history of intolerance, hypersensitivity, or treatment discontinuation due to&#xD;
             severe immune adverse events on prior immunotherapy, or documented presence of&#xD;
             neutralizing anti-drug antibody to nivolumab, ipilimumab, or pembrolizumab. Subjects&#xD;
             who discontinued prior immunotherapies for immune-related adverse events that are&#xD;
             well-controlled with appropriate treatment may be enrolled if approved by the Medical&#xD;
             Monitor.&#xD;
&#xD;
          6. Have a diagnosis of immunodeficiency, either primary or acquired, or treatment with&#xD;
             systemic steroids or any other form of immunosuppressive therapy within 7 days prior&#xD;
             to C1D1. Exception: inhaled or topical steroids and adrenal replacement doses are&#xD;
             permitted in the absence of active autoimmune disease as well as a one-time dose of&#xD;
             immunosuppressive agents used prophylactically for contrast allergies&#xD;
&#xD;
          7. Have any active disease requiring systemic immunosuppressive treatment&#xD;
&#xD;
          8. Have known severe intolerance to or life-threatening hypersensitivity reactions to&#xD;
             humanized monoclonal antibodies or intravenous immunoglobulin preparations; any&#xD;
             history of anaphylaxis; prior history of human anti-human antibody response; known&#xD;
             allergy to any of the study medications, their analogues, or excipients in the various&#xD;
             formulations of any agent&#xD;
&#xD;
          9. Are symptomatic or have uncontrolled brain metastases, leptomeningeal disease, or&#xD;
             spinal cord compression not definitively treated with surgery or radiation (brain&#xD;
             metastases that are stable and asymptomatic, either treated or untreated, will be&#xD;
             allowed)&#xD;
&#xD;
         10. Have current second malignancy at other sites, which requires treatment, or in the&#xD;
             judgement of the Investigator, may require treatment within the next year. Concurrent&#xD;
             malignancies that do not require treatment and are clinically stable are allowed. A&#xD;
             past history of other malignancies is allowed as long as the subject is not receiving&#xD;
             specific treatment other than hormonal therapy, and, in the judgement of the&#xD;
             Investigator, is unlikely to have a recurrence.&#xD;
&#xD;
         11. Have active and clinically relevant bacterial, fungal, or viral infection, including&#xD;
             known Hepatitis A, B, or C or human immunodeficiency virus (HIV) (testing not&#xD;
             required)&#xD;
&#xD;
         12. Have received live vaccines within past 30 days (inactivated vaccines are allowed;&#xD;
             seasonal vaccines should be up to date prior to first infusion day)&#xD;
&#xD;
         13. Women who are pregnant or breastfeeding&#xD;
&#xD;
         14. Have experienced symptomatic cardiac disease that is unresponsive to surgical or&#xD;
             medical management&#xD;
&#xD;
         15. Have any medical or social condition that, in the opinion of the Investigator, might&#xD;
             place a subject at increased risk, affect compliance, or confound safety or other&#xD;
             clinical trial data interpretation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Trehu, MD, FACP</last_name>
    <role>Study Director</role>
    <affiliation>Jounce Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at HealthONE</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medicine Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at TriStar Health</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>September 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <results_first_submitted>June 2, 2021</results_first_submitted>
  <results_first_submitted_qc>September 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2021</results_first_posted>
  <last_update_submitted>September 5, 2021</last_update_submitted>
  <last_update_submitted_qc>September 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICOS</keyword>
  <keyword>ICOS agonist monoclonal antibody</keyword>
  <keyword>JTX-2011</keyword>
  <keyword>Anti-PD-1</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>ICONIC</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Immuno-oncology</keyword>
  <keyword>Cancer</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Dose Escalation</keyword>
  <keyword>Dose Expansion</keyword>
  <keyword>Anti-CTLA-4</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>Pembrolizumab</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT02904226/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT02904226/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The protocol enrollment number of 242 is the number of participants who signed the ICF. The number that Started the Participant flow module (218) are those subjects who received any amount of study drug (JTX-2011 and/or nivolumab and/or ipilimumab and/or pembrolizumab). The difference between these two values (24) are the number of patients who screen failed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A (JTX-2011)</title>
          <description>Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion&#xD;
JTX-2011: Specified dose on specified days</description>
        </group>
        <group group_id="P2">
          <title>Part B (JTX-2011 + Nivolumab)</title>
          <description>Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
        </group>
        <group group_id="P3">
          <title>Part C (JTX-2011)</title>
          <description>Phase 2 expansion of JTX-2011 by IV infusion&#xD;
JTX-2011: Specified dose on specified days</description>
        </group>
        <group group_id="P4">
          <title>Part D (JTX-2011 + Nivolumab)</title>
          <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
        </group>
        <group group_id="P5">
          <title>Part E (JTX-2011 + Ipilimumab)</title>
          <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Ipilimumab: Specified dose on specified days</description>
        </group>
        <group group_id="P6">
          <title>Part F (JTX-2011 + Ipilimumab)</title>
          <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion JTX-2011: Specified dose on specified days Ipilimumab: Specified dose on specified days</description>
        </group>
        <group group_id="P7">
          <title>Part G (JTX-2011 + Pembrolizumab)</title>
          <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Pembrolizumab: Specified dose on specified days</description>
        </group>
        <group group_id="P8">
          <title>Part H (JTX-2011 + Pembrolizumab)</title>
          <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion JTX-2011: Specified dose on specified days Pembrolizumab: Specified dose on specified days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="100"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="96"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Parts F and H were never opened as clinical and translational data from ICONIC suggests that alternative regimens may be preferable to those proposed in Parts F and H.</population>
      <group_list>
        <group group_id="B1">
          <title>Part A (JTX-2011)</title>
          <description>Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion&#xD;
JTX-2011: Specified dose on specified days</description>
        </group>
        <group group_id="B2">
          <title>Part B (JTX-2011 + Nivolumab)</title>
          <description>Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
        </group>
        <group group_id="B3">
          <title>Part C (JTX-2011)</title>
          <description>Phase 2 expansion of JTX-2011 by IV infusion&#xD;
JTX-2011: Specified dose on specified days</description>
        </group>
        <group group_id="B4">
          <title>Part D (JTX-2011 + Nivolumab)</title>
          <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
        </group>
        <group group_id="B5">
          <title>Part E (JTX-2011 + Ipilimumab)</title>
          <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Ipilimumab: Specified dose on specified days</description>
        </group>
        <group group_id="B6">
          <title>Part F (JTX-2011 + Ipilimumab)</title>
          <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Ipilimumab: Specified dose on specified days</description>
        </group>
        <group group_id="B7">
          <title>Part G (JTX-2011 + Pembrolizumab)</title>
          <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Pembrolizumab: Specified dose on specified days</description>
        </group>
        <group group_id="B8">
          <title>Part H (JTX-2011 + Pembrolizumab)</title>
          <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Pembrolizumab: Specified dose on specified days</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="100"/>
            <count group_id="B5" value="11"/>
            <count group_id="B6" value="0"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="0"/>
            <count group_id="B9" value="218"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B9" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B9" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.6" spread="10.94"/>
                    <measurement group_id="B2" value="56.2" spread="9.87"/>
                    <measurement group_id="B3" value="64.4" spread="10.57"/>
                    <measurement group_id="B4" value="61.1" spread="9.65"/>
                    <measurement group_id="B5" value="58.8" spread="9.95"/>
                    <measurement group_id="B7" value="65.7" spread="8.77"/>
                    <measurement group_id="B9" value="60.8" spread="10.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B9" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="61"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B9" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B9" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="91"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B9" value="196"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B9" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B9" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B9" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="77"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B9" value="163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B9" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="100"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B9" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAE)</title>
        <description>Number of participants with an adverse event occurring from the time of informed consent until resolution or new therapy initiated or for 28 days post final dose if no new therapy is initiated</description>
        <time_frame>46.3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A (JTX-2011)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O2">
            <title>Part B (JTX-2011 + Nivolumab)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O3">
            <title>Part C (JTX-2011)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O4">
            <title>Part D (JTX-2011 + Nivolumab)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O5">
            <title>Part E (JTX-2011 + Ipilimumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Ipilimumab: Specified dose on specified days</description>
          </group>
          <group group_id="O6">
            <title>Part G (JTX-2011 + Pembrolizumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Pembrolizumab: Specified dose on specified days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAE)</title>
          <description>Number of participants with an adverse event occurring from the time of informed consent until resolution or new therapy initiated or for 28 days post final dose if no new therapy is initiated</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="98"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grade 5 (Fatal) Treatment Emergent Adverse Events (TEAE)</title>
        <description>Number of participants with Grade 5 (fatal) treatment emergent adverse events (TEAE) assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</description>
        <time_frame>46.3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A (JTX-2011)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O2">
            <title>Part B (JTX-2011 + Nivolumab)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O3">
            <title>Part C (JTX-2011)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O4">
            <title>Part D (JTX-2011 + Nivolumab)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O5">
            <title>Part E (JTX-2011 + Ipilimumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Ipilimumab: Specified dose on specified days</description>
          </group>
          <group group_id="O6">
            <title>Part G (JTX-2011 + Pembrolizumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Pembrolizumab: Specified dose on specified days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 5 (Fatal) Treatment Emergent Adverse Events (TEAE)</title>
          <description>Number of participants with Grade 5 (fatal) treatment emergent adverse events (TEAE) assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grade 4 (Life Threatening) Treatment Emergent Adverse Events (TEAE)</title>
        <description>Number of participants with Grade 4 (life threatening) treatment emergent adverse events (TEAE) assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</description>
        <time_frame>46.3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A (JTX-2011)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O2">
            <title>Part B (JTX-2011 + Nivolumab)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O3">
            <title>Part C (JTX-2011)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O4">
            <title>Part D (JTX-2011 + Nivolumab)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O5">
            <title>Part E (JTX-2011 + Ipilimumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Ipilimumab: Specified dose on specified days</description>
          </group>
          <group group_id="O6">
            <title>Part G (JTX-2011 + Pembrolizumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Pembrolizumab: Specified dose on specified days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 4 (Life Threatening) Treatment Emergent Adverse Events (TEAE)</title>
          <description>Number of participants with Grade 4 (life threatening) treatment emergent adverse events (TEAE) assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grade 3 (Sever) Treatment Emergent Adverse Events (TEAE)</title>
        <description>Number of participants with Grade 3 (severe) treatment emergent adverse events (TEAE) assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.&quot;</description>
        <time_frame>46.3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A (JTX-2011)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O2">
            <title>Part B (JTX-2011 + Nivolumab)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O3">
            <title>Part C (JTX-2011)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O4">
            <title>Part D (JTX-2011 + Nivolumab)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O5">
            <title>Part E (JTX-2011 + Ipilimumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Ipilimumab: Specified dose on specified days</description>
          </group>
          <group group_id="O6">
            <title>Part G (JTX-2011 + Pembrolizumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Pembrolizumab: Specified dose on specified days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 (Sever) Treatment Emergent Adverse Events (TEAE)</title>
          <description>Number of participants with Grade 3 (severe) treatment emergent adverse events (TEAE) assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="43"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grade 2 (Moderate) Treatment Emergent Adverse Events (TEAE)</title>
        <description>Number of participants with Grade 2 (moderate) treatment emergent adverse events (TEAE) assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03</description>
        <time_frame>46.3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A (JTX-2011)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O2">
            <title>Part B (JTX-2011 + Nivolumab)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O3">
            <title>Part C (JTX-2011)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O4">
            <title>Part D (JTX-2011 + Nivolumab)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O5">
            <title>Part E (JTX-2011 + Ipilimumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Ipilimumab: Specified dose on specified days</description>
          </group>
          <group group_id="O6">
            <title>Part G (JTX-2011 + Pembrolizumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Pembrolizumab: Specified dose on specified days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 2 (Moderate) Treatment Emergent Adverse Events (TEAE)</title>
          <description>Number of participants with Grade 2 (moderate) treatment emergent adverse events (TEAE) assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="32"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grade 1 (Mild) Treatment Emergent Adverse Events (TEAE)</title>
        <description>Number of participants with Grade 1 (mild) treatment emergent adverse events (TEAE) assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03</description>
        <time_frame>46.3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A (JTX-2011)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O2">
            <title>Part B (JTX-2011 + Nivolumab)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O3">
            <title>Part C (JTX-2011)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O4">
            <title>Part D (JTX-2011 + Nivolumab)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O5">
            <title>Part E (JTX-2011 + Ipilimumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Ipilimumab: Specified dose on specified days</description>
          </group>
          <group group_id="O6">
            <title>Part G (JTX-2011 + Pembrolizumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Pembrolizumab: Specified dose on specified days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 1 (Mild) Treatment Emergent Adverse Events (TEAE)</title>
          <description>Number of participants with Grade 1 (mild) treatment emergent adverse events (TEAE) assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Dose Limiting Toxicities</title>
        <description>Number of participants with at least one dose limiting toxicity (DLT)</description>
        <time_frame>33 months</time_frame>
        <population>Part C and D did not have any participants analyzed for this outcome measure because DLT is only relevant to the Phase 1 parts of study (Part A, Part B, Part E and Part G).</population>
        <group_list>
          <group group_id="O1">
            <title>Part A (JTX-2011)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O2">
            <title>Part B (JTX-2011 + Nivolumab)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O3">
            <title>Part C (JTX-2011)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O4">
            <title>Part D (JTX-2011 + Nivolumab)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O5">
            <title>Part E (JTX-2011 + Ipilimumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Ipilimumab: Specified dose on specified days</description>
          </group>
          <group group_id="O6">
            <title>Part G (JTX-2011 + Pembrolizumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Pembrolizumab: Specified dose on specified days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose Limiting Toxicities</title>
          <description>Number of participants with at least one dose limiting toxicity (DLT)</description>
          <population>Part C and D did not have any participants analyzed for this outcome measure because DLT is only relevant to the Phase 1 parts of study (Part A, Part B, Part E and Part G).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate</title>
        <description>Overall response rate (ORR) is defined as the proportion of subjects with a Best Overall Response characterized as either a Complete Response (CR) or Partial Response (PR) as defined by RECISTv1.1 guidelines based on investigator's review</description>
        <time_frame>46.5 months</time_frame>
        <population>Response Evaluable Set: subjects who received any study drug and have a baseline tumor assessment, and either has at least one post-baseline tumor assessment scan and/or discontinued treatment due to death or disease progression The number of participants analyzed is zero for Part F and Part H because there were no participants enrolled in those two groups of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Part A (JTX-2011)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O2">
            <title>Part B (JTX-2011 + Nivolumab)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O3">
            <title>Part C (JTX-2011)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O4">
            <title>Part D (JTX-2011 + Nivolumab)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O5">
            <title>Part E (JTX-2011 + Ipilimumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Ipilimumab: Specified dose on specified days</description>
          </group>
          <group group_id="O6">
            <title>Part G (JTX-2011 + Pembrolizumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Pembrolizumab: Specified dose on specified days</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Overall response rate (ORR) is defined as the proportion of subjects with a Best Overall Response characterized as either a Complete Response (CR) or Partial Response (PR) as defined by RECISTv1.1 guidelines based on investigator's review</description>
          <population>Response Evaluable Set: subjects who received any study drug and have a baseline tumor assessment, and either has at least one post-baseline tumor assessment scan and/or discontinued treatment due to death or disease progression The number of participants analyzed is zero for Part F and Part H because there were no participants enrolled in those two groups of the study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease Control Rate</title>
        <description>Disease Control Rate: Percent Subjects with confirmed Complete Response + confirmed Partial Response + BoR of SD (or unconfirmed complete response or partial response lasting at least 53 days from the date of first dose)</description>
        <time_frame>46.5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A (JTX-2011)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O2">
            <title>Part B (JTX-2011 + Nivolumab)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O3">
            <title>Part C (JTX-2011)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O4">
            <title>Part D (JTX-2011 + Nivolumab)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O5">
            <title>Part E (JTX-2011 + Ipilimumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Ipilimumab: Specified dose on specified days</description>
          </group>
          <group group_id="O6">
            <title>Part G (JTX-2011 + Pembrolizumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Pembrolizumab: Specified dose on specified days</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate</title>
          <description>Disease Control Rate: Percent Subjects with confirmed Complete Response + confirmed Partial Response + BoR of SD (or unconfirmed complete response or partial response lasting at least 53 days from the date of first dose)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival</title>
        <description>Progression free survival, as determined by the Investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)</description>
        <time_frame>46.5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A (JTX-2011)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O2">
            <title>Part B (JTX-2011 + Nivolumab)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O3">
            <title>Part C (JTX-2011)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O4">
            <title>Part D (JTX-2011 + Nivolumab)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O5">
            <title>Part E (JTX-2011 + Ipilimumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Ipilimumab: Specified dose on specified days</description>
          </group>
          <group group_id="O6">
            <title>Part G (JTX-2011 + Pembrolizumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Pembrolizumab: Specified dose on specified days</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Progression free survival, as determined by the Investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.9" upper_limit="2.1"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.8" upper_limit="2.2"/>
                    <measurement group_id="O3" value="1.9" lower_limit="1.8" upper_limit="2.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.9" upper_limit="2.0"/>
                    <measurement group_id="O5" value="2.5" lower_limit="1.3" upper_limit="4.1"/>
                    <measurement group_id="O6" value="4.0" lower_limit="1.3" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>6 Month Landmark Progression Free Survival</title>
        <description>Percentage of patients that are progression free at 6 months, estimated by the Kaplan Meier method as the probability of being event-free at 6 months out of the entire 45.5-month primary study period. This method generates survival probability estimates across the Time Frame of the study using all data throughout the course of the trial.</description>
        <time_frame>46.5 months</time_frame>
        <population>The 95% CI is not estimable by Kaplan-Meier method for Part E since the probability of event was 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A (JTX-2011)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O2">
            <title>Part B (JTX-2011 + Nivolumab)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O3">
            <title>Part C (JTX-2011)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O4">
            <title>Part D (JTX-2011 + Nivolumab)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O5">
            <title>Part E (JTX-2011 + Ipilimumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Ipilimumab: Specified dose on specified days</description>
          </group>
          <group group_id="O6">
            <title>Part G (JTX-2011 + Pembrolizumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Pembrolizumab: Specified dose on specified days</description>
          </group>
        </group_list>
        <measure>
          <title>6 Month Landmark Progression Free Survival</title>
          <description>Percentage of patients that are progression free at 6 months, estimated by the Kaplan Meier method as the probability of being event-free at 6 months out of the entire 45.5-month primary study period. This method generates survival probability estimates across the Time Frame of the study using all data throughout the course of the trial.</description>
          <population>The 95% CI is not estimable by Kaplan-Meier method for Part E since the probability of event was 0.</population>
          <units>Probability of event free at month 6 (%)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="2.1" upper_limit="25.3"/>
                    <measurement group_id="O2" value="10.2" lower_limit="2.0" upper_limit="26.5"/>
                    <measurement group_id="O3" value="4.1" lower_limit=".3" upper_limit="17.6"/>
                    <measurement group_id="O4" value="9.1" lower_limit="3.8" upper_limit="17.3"/>
                    <measurement group_id="O5" value="0" lower_limit="NA" upper_limit="NA">NA Explanation: The 95% CI is not estimable by Kaplan-Meier method since no patients are at risk by the 6 month landmark</measurement>
                    <measurement group_id="O6" value="33.3" lower_limit="1.4" upper_limit="75.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>12 Month Landmark Progression Free Survival</title>
        <description>Percentage of patients that are progression free at 12 month, estimated by the Kaplan Meier method as the probability of being event-free at 12 months out of the entire 45.5-month primary study period. This method generates survival probability estimates across the Time Frame of the study using all data throughout the course of the trial.</description>
        <time_frame>46.5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A (JTX-2011)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O2">
            <title>Part B (JTX-2011 + Nivolumab)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O3">
            <title>Part C (JTX-2011)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O4">
            <title>Part D (JTX-2011 + Nivolumab)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O5">
            <title>Part E (JTX-2011 + Ipilimumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Ipilimumab: Specified dose on specified days</description>
          </group>
          <group group_id="O6">
            <title>Part G (JTX-2011 + Pembrolizumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Pembrolizumab: Specified dose on specified days</description>
          </group>
        </group_list>
        <measure>
          <title>12 Month Landmark Progression Free Survival</title>
          <description>Percentage of patients that are progression free at 12 month, estimated by the Kaplan Meier method as the probability of being event-free at 12 months out of the entire 45.5-month primary study period. This method generates survival probability estimates across the Time Frame of the study using all data throughout the course of the trial.</description>
          <units>Probability of event free at month 12(%)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">The 95% CI is not estimable by Kaplan-Meier method since no patients are at risk by the 12 month landmark</measurement>
                    <measurement group_id="O2" value="10.2" lower_limit="2.0" upper_limit="26.5"/>
                    <measurement group_id="O3" value="4.1" lower_limit=".3" upper_limit="17.5"/>
                    <measurement group_id="O4" value="4.6" lower_limit="1.2" upper_limit="11.4"/>
                    <measurement group_id="O5" value="0" lower_limit="NA" upper_limit="NA">The 95% CI is not estimable by Kaplan-Meier method since no patients are at risk by the 12 month landmark</measurement>
                    <measurement group_id="O6" value="0" lower_limit="NA" upper_limit="NA">The 95% CI is not estimable by Kaplan-Meier method since no patients are at risk by the 12 month landmark</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Landmark Overall Survival at 6 Months</title>
        <description>Percentage of patients that are alive at 6 month, estimated by the Kaplan Meier method as the probability of being event-free at 6 months out of the entire 45.5-month primary study period. This method generates survival probability estimates across the Time Frame of the study using all data throughout the course of the trial.</description>
        <time_frame>46.5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A (JTX-2011)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O2">
            <title>Part B (JTX-2011 + Nivolumab)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O3">
            <title>Part C (JTX-2011)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O4">
            <title>Part D (JTX-2011 + Nivolumab)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O5">
            <title>Part E (JTX-2011 + Ipilimumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Ipilimumab: Specified dose on specified days</description>
          </group>
          <group group_id="O6">
            <title>Part G (JTX-2011 + Pembrolizumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Pembrolizumab: Specified dose on specified days</description>
          </group>
        </group_list>
        <measure>
          <title>Landmark Overall Survival at 6 Months</title>
          <description>Percentage of patients that are alive at 6 month, estimated by the Kaplan Meier method as the probability of being event-free at 6 months out of the entire 45.5-month primary study period. This method generates survival probability estimates across the Time Frame of the study using all data throughout the course of the trial.</description>
          <units>Probability of event free at month 6 (%)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.4" lower_limit="46.8" upper_limit="83.9"/>
                    <measurement group_id="O2" value="61.8" lower_limit="40.4" upper_limit="77.5"/>
                    <measurement group_id="O3" value="47.9" lower_limit="27.2" upper_limit="66.0"/>
                    <measurement group_id="O4" value="70.2" lower_limit="59.1" upper_limit="78.8"/>
                    <measurement group_id="O5" value="77.8" lower_limit="36.5" upper_limit="93.9"/>
                    <measurement group_id="O6" value="66.7" lower_limit="19.5" upper_limit="90.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Landmark Overall Survival at 12 Months</title>
        <description>Percentage of patients that are alive at 12 month, estimated by the Kaplan Meier method as the probability of being event-free at 12 months out of the entire 45.5-month primary study period. This method generates survival probability estimates across the Time Frame of the study using all data throughout the course of the trial.</description>
        <time_frame>46.5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A (JTX-2011)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O2">
            <title>Part B (JTX-2011 + Nivolumab)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O3">
            <title>Part C (JTX-2011)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O4">
            <title>Part D (JTX-2011 + Nivolumab)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O5">
            <title>Part E (JTX-2011 + Ipilimumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Ipilimumab: Specified dose on specified days</description>
          </group>
          <group group_id="O6">
            <title>Part G (JTX-2011 + Pembrolizumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Pembrolizumab: Specified dose on specified days</description>
          </group>
        </group_list>
        <measure>
          <title>Landmark Overall Survival at 12 Months</title>
          <description>Percentage of patients that are alive at 12 month, estimated by the Kaplan Meier method as the probability of being event-free at 12 months out of the entire 45.5-month primary study period. This method generates survival probability estimates across the Time Frame of the study using all data throughout the course of the trial.</description>
          <units>Probability of event free at month 12(%)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="2.1" upper_limit="31.8"/>
                    <measurement group_id="O2" value="41.2" lower_limit="22.2" upper_limit="59.3"/>
                    <measurement group_id="O3" value="16.0" lower_limit="4.1" upper_limit="34.8"/>
                    <measurement group_id="O4" value="40.5" lower_limit="29.5" upper_limit="51.3"/>
                    <measurement group_id="O5" value="31.1" lower_limit="1.5" upper_limit="72.3"/>
                    <measurement group_id="O6" value="16.7" lower_limit=".8" upper_limit="51.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>The time from first dose date to the date of death for any cause</description>
        <time_frame>46.5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part A (JTX-2011)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O2">
            <title>Part B (JTX-2011 + Nivolumab)</title>
            <description>Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O3">
            <title>Part C (JTX-2011)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion&#xD;
JTX-2011: Specified dose on specified days</description>
          </group>
          <group group_id="O4">
            <title>Part D (JTX-2011 + Nivolumab)</title>
            <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
          </group>
          <group group_id="O5">
            <title>Part E (JTX-2011 + Ipilimumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Ipilimumab: Specified dose on specified days</description>
          </group>
          <group group_id="O6">
            <title>Part G (JTX-2011 + Pembrolizumab)</title>
            <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Pembrolizumab: Specified dose on specified days</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The time from first dose date to the date of death for any cause</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="5.4" upper_limit="10.3"/>
                    <measurement group_id="O2" value="8.9" lower_limit="4.7" upper_limit="12.7"/>
                    <measurement group_id="O3" value="4.9" lower_limit="3.1" upper_limit="9.2"/>
                    <measurement group_id="O4" value="9.5" lower_limit="7.2" upper_limit="12.0"/>
                    <measurement group_id="O5" value="9.3" lower_limit="1.9" upper_limit="NA">Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                    <measurement group_id="O6" value="8.2" lower_limit="2.9" upper_limit="NA">Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants could be monitored for up to 46.5 months (the time from signing consent to 28 days after the last dose is administered)</time_frame>
      <desc>The first patient signed informed consent on 2016-08-17; 28 days after the last dose was 2020-07-01, therefore AE reporting took place over the course of 46.5 months. AE data was collected via adverse event case report forms using log forms. The number of participants at risk for Serious AEs, All-Cause Mortality, and Other (Not Including Serious) AEs is zero for Part F and Part H because no subjects were enrolled in these parts of the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part A (JTX-2011)</title>
          <description>Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion&#xD;
JTX-2011: Specified dose on specified days</description>
        </group>
        <group group_id="E2">
          <title>Part B (JTX-2011 + Nivolumab)</title>
          <description>Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
        </group>
        <group group_id="E3">
          <title>Part C (JTX-2011)</title>
          <description>Phase 2 expansion of JTX-2011 by IV infusion&#xD;
JTX-2011: Specified dose on specified days</description>
        </group>
        <group group_id="E4">
          <title>Part D (JTX-2011 + Nivolumab)</title>
          <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Nivolumab: Specified dose on specified days</description>
        </group>
        <group group_id="E5">
          <title>Part E (JTX-2011 + Ipilimumab)</title>
          <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Ipilimumab: Specified dose on specified days</description>
        </group>
        <group group_id="E6">
          <title>Part F (JTX-2011 + Ipilimumab)</title>
          <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Ipilimumab: Specified dose on specified days</description>
        </group>
        <group group_id="E7">
          <title>Part G (JTX-2011 + Pembrolizumab)</title>
          <description>Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Pembrolizumab: Specified dose on specified days</description>
        </group>
        <group group_id="E8">
          <title>Part H (JTX-2011 + Pembrolizumab)</title>
          <description>Phase 2 expansion of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion&#xD;
JTX-2011: Specified dose on specified days&#xD;
Pembrolizumab: Specified dose on specified days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="68" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericarditis</sub_title>
                <description>Pericarditis</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Tracheo-oesophageal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Duodenal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Chondrosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tumor associated fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tumor hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Paraneoplastic pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pharyngeal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Spinal fusion surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="98" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyerthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Intermittent nausea</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication (&quot;pub.&quot;) can be restricted until the 1st to occur of (a) pub. of the clinical trial results, or (b) 18 mo's after the Primary Completion Date. Pub. rights depend on PI conducting the study in compliance with the Protocol, that the pub. is made in a recognized journal or conference, and makes use of all study data. The Sponsor can require removal of Sponsor's confidential information from any pub. and can defer pub. for up to an add'l 60 days to file a related patent application.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ellen Hooper, Senior Medical Director</name_or_title>
      <organization>Jounce Therapeutics</organization>
      <phone>857-320-2548</phone>
      <email>ehooper@jouncetx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

